

**ScienceDirect**Contents lists available at [sciencedirect.com](https://www.sciencedirect.com)  
Journal homepage: [www.elsevier.com/locate/jval](https://www.elsevier.com/locate/jval)

VALUE HEALTH. 2022; ■(■):1

**Correction****Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting***Value Health*. 2022;25(6):965-974.DOI of original article: [10.1016/j.jval.2021.11.1364](https://doi.org/10.1016/j.jval.2021.11.1364)

The funding/support statement published with this paper did not accurately reflect the role of the funder. The corrected statement should read: "Mallinckrodt Pharmaceuticals provided funding and oversight to Health Technology Analysts for the development of the reimbursement application to the Medical Services Advisory Committee, on which this study is based. The funder was also involved in the review and approval of the manuscript. The decision to submit the manuscript for publication was based on the outcome of the reimbursement application."

doi: <https://doi.org/10.1016/j.jval.2022.09.006>